Cryptococcal therapies and drug targets: the old, the new and the promising

Carolina Coelho, Arturo Casadevall

Research output: Contribution to journalReview articlepeer-review

Abstract

Half a century after the introduction of Amphotericin B the management of cryptococcosis remains unsatisfactory. The disease, caused primarily by the two fungal species Cryptococcus neoformans and Cryptococcus gattii, remains responsible for considerable morbidity and mortality despite standard medical care. Current therapeutic options are limited to Amphotericin B, azoles and 5-flucytosine. However, this organism has numerous well-characterized virulence mechanisms that are amenable to pharmacological interference and are thus potential therapeutic targets. Here, we discuss existing approved antifungal drugs, resistance mechanisms to these drugs and non-standard antifungal drugs that have potential in treatment of cryptococcosis, including immunomodulatory strategies that synergize with antifungal drugs, such as cytokine administration or monoclonal antibodies. Finally, we summarize attempts to target well-described virulence factors of Cryptococcus, the capsule or fungal melanin. This review emphasizes the pressing need for new therapeutic alternatives for cryptococcosis.

Original languageEnglish (US)
Pages (from-to)792-799
Number of pages8
JournalCellular microbiology
Volume18
Issue number6
DOIs
StatePublished - Jun 1 2016

ASJC Scopus subject areas

  • Microbiology
  • Immunology
  • Virology

Fingerprint Dive into the research topics of 'Cryptococcal therapies and drug targets: the old, the new and the promising'. Together they form a unique fingerprint.

Cite this